Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 3.42
LXRX's Cash-to-Debt is ranked lower than
66% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. LXRX: 3.42 )
Ranked among companies with meaningful Cash-to-Debt only.
LXRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.85  Med: 4.24 Max: No Debt
Current: 3.42
Equity-to-Asset 0.33
LXRX's Equity-to-Asset is ranked lower than
82% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. LXRX: 0.33 )
Ranked among companies with meaningful Equity-to-Asset only.
LXRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.63 Max: 0.94
Current: 0.33
0.33
0.94
Piotroski F-Score: 1
Altman Z-Score: -1.13
Beneish M-Score: 8.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -164.58
LXRX's Operating Margin % is ranked lower than
57% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. LXRX: -164.58 )
Ranked among companies with meaningful Operating Margin % only.
LXRX' s Operating Margin % Range Over the Past 10 Years
Min: -9955.46  Med: -639.94 Max: 1.13
Current: -164.58
-9955.46
1.13
Net Margin % -169.71
LXRX's Net Margin % is ranked lower than
58% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. LXRX: -169.71 )
Ranked among companies with meaningful Net Margin % only.
LXRX' s Net Margin % Range Over the Past 10 Years
Min: -10120.39  Med: -606.25 Max: -3.6
Current: -169.71
-10120.39
-3.6
ROE % -64.37
LXRX's ROE % is ranked lower than
68% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. LXRX: -64.37 )
Ranked among companies with meaningful ROE % only.
LXRX' s ROE % Range Over the Past 10 Years
Min: -64.37  Med: -43.42 Max: -1.64
Current: -64.37
-64.37
-1.64
ROA % -25.13
LXRX's ROA % is ranked higher than
54% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. LXRX: -25.13 )
Ranked among companies with meaningful ROA % only.
LXRX' s ROA % Range Over the Past 10 Years
Min: -32.59  Med: -27.19 Max: -0.83
Current: -25.13
-32.59
-0.83
ROC (Joel Greenblatt) % -663.86
LXRX's ROC (Joel Greenblatt) % is ranked lower than
56% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. LXRX: -663.86 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LXRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -664.07  Med: -202.19 Max: 15.03
Current: -663.86
-664.07
15.03
3-Year Revenue Growth Rate 199.00
LXRX's 3-Year Revenue Growth Rate is ranked higher than
98% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. LXRX: 199.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LXRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -71.6  Med: 13 Max: 328.1
Current: 199
-71.6
328.1
3-Year EBITDA Growth Rate -1.90
LXRX's 3-Year EBITDA Growth Rate is ranked lower than
51% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. LXRX: -1.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LXRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -28.5  Med: -8.7 Max: 22.5
Current: -1.9
-28.5
22.5
3-Year EPS without NRI Growth Rate -1.40
LXRX's 3-Year EPS without NRI Growth Rate is ranked higher than
52% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. LXRX: -1.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LXRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.6  Med: -11.1 Max: 29.1
Current: -1.4
-68.6
29.1
GuruFocus has detected 4 Warning Signs with Lexicon Pharmaceuticals Inc $LXRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LXRX's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

LXRX Guru Trades in Q1 2016

Joel Greenblatt 189,317 sh (New)
Chuck Royce 340,589 sh (+31.20%)
Mario Gabelli 16,100 sh (unchged)
» More
Q2 2016

LXRX Guru Trades in Q2 2016

Paul Tudor Jones 12,351 sh (New)
Joel Greenblatt 295,094 sh (+55.87%)
Mario Gabelli 16,100 sh (unchged)
Chuck Royce Sold Out
» More
Q3 2016

LXRX Guru Trades in Q3 2016

Paul Tudor Jones 41,850 sh (+238.84%)
Mario Gabelli 14,600 sh (-9.32%)
Joel Greenblatt 47,635 sh (-83.86%)
» More
Q4 2016

LXRX Guru Trades in Q4 2016

Mario Gabelli 14,600 sh (unchged)
Paul Tudor Jones 30,574 sh (-26.94%)
Joel Greenblatt 27,102 sh (-43.10%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:LXRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:FGEN, NAS:GBT, NAS:ARRY, NAS:INVA, NAS:SRPT, OTCPK:BVNRY, NYSE:AXON, NAS:ONCE, NAS:BGNE, NAS:HALO, OTCPK:MPSYY, NAS:DERM, NAS:DBVT, NAS:PBYI, NAS:AAAP, OTCPK:VNAPF, NAS:BPMC, NYSE:CBM, NAS:CORT, NAS:RGEN » details
Traded in other countries:LX31.Germany,
Headquarter Location:USA
Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease.

Lexicon Pharmaceuticals is a biopharmaceutical company that uses mouse genetics to discover the function of genes and find promising drug targets. Lexicon then designs and develops drugs for these targets, which cover a broad spectrum of therapeutic areas. Following a restructuring in January 2014, Lexicon is focusing efforts on two drug candidates: sotagliflozin (LX4211) in diabetes, which is partnered with Sanofi, and telotristat etiprate in carcinoid syndrome, which is partnered with Ipsen.

Ratios

vs
industry
vs
history
PB Ratio 10.38
LXRX's PB Ratio is ranked lower than
84% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. LXRX: 10.38 )
Ranked among companies with meaningful PB Ratio only.
LXRX' s PB Ratio Range Over the Past 10 Years
Min: 0.66  Med: 3.29 Max: 11.16
Current: 10.38
0.66
11.16
PS Ratio 19.52
LXRX's PS Ratio is ranked lower than
60% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. LXRX: 19.52 )
Ranked among companies with meaningful PS Ratio only.
LXRX' s PS Ratio Range Over the Past 10 Years
Min: 2.62  Med: 24.28 Max: 1440
Current: 19.52
2.62
1440
EV-to-EBIT -9.79
LXRX's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. LXRX: -9.79 )
Ranked among companies with meaningful EV-to-EBIT only.
LXRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -229  Med: -3.1 Max: 484.5
Current: -9.79
-229
484.5
EV-to-EBITDA -9.93
LXRX's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. LXRX: -9.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
LXRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -281.1  Med: -3.3 Max: 357.2
Current: -9.93
-281.1
357.2
Current Ratio 2.17
LXRX's Current Ratio is ranked lower than
72% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. LXRX: 2.17 )
Ranked among companies with meaningful Current Ratio only.
LXRX' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 5.83 Max: 19.93
Current: 2.17
1.19
19.93
Quick Ratio 2.17
LXRX's Quick Ratio is ranked lower than
68% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. LXRX: 2.17 )
Ranked among companies with meaningful Quick Ratio only.
LXRX' s Quick Ratio Range Over the Past 10 Years
Min: 1.19  Med: 5.83 Max: 19.93
Current: 2.17
1.19
19.93
Days Sales Outstanding 32.81
LXRX's Days Sales Outstanding is ranked higher than
77% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. LXRX: 32.81 )
Ranked among companies with meaningful Days Sales Outstanding only.
LXRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.56  Med: 30.31 Max: 461.86
Current: 32.81
2.56
461.86

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.40
LXRX's 3-Year Average Share Buyback Ratio is ranked lower than
54% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. LXRX: -12.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LXRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -52  Med: -15 Max: -6.9
Current: -12.4
-52
-6.9

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 58.04
LXRX's Price-to-Net-Cash is ranked lower than
92% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. LXRX: 58.04 )
Ranked among companies with meaningful Price-to-Net-Cash only.
LXRX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.84  Med: 4.68 Max: 58.3
Current: 58.04
2.84
58.3
Price-to-Net-Current-Asset-Value 41.24
LXRX's Price-to-Net-Current-Asset-Value is ranked lower than
93% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. LXRX: 41.24 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
LXRX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.45  Med: 5.12 Max: 59.01
Current: 41.24
2.45
59.01
Price-to-Tangible-Book 27.49
LXRX's Price-to-Tangible-Book is ranked lower than
92% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. LXRX: 27.49 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LXRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.2  Med: 3.54 Max: 27.61
Current: 27.49
1.2
27.61
Price-to-Median-PS-Value 0.80
LXRX's Price-to-Median-PS-Value is ranked higher than
68% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. LXRX: 0.80 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LXRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 0.71 Max: 42.97
Current: 0.8
0.13
42.97
Earnings Yield (Greenblatt) % -10.20
LXRX's Earnings Yield (Greenblatt) % is ranked lower than
60% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. LXRX: -10.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LXRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -10.78  Med: 19.8 Max: 1944.4
Current: -10.2
-10.78
1944.4

More Statistics

Revenue (TTM) (Mil) $83.34
EPS (TTM) $ -1.37
Beta0.01
Short Percentage of Float54.18%
52-Week Range $11.52 - 19.62
Shares Outstanding (Mil)104.32

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 78 106 233
EPS ($) -1.54 -1.30 0.19
EPS without NRI ($) -1.54 -1.30 0.19
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:LXRX

Headlines

Articles On GuruFocus.com
Lexicon To Present At The 16th Annual Needham Healthcare Conference Apr 03 2017 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Nov 08 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) May 10 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Oct 30 2009 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Aug 06 2009 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Apr 30 2009 

More From Other Websites
Lexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : April 26, 2017 Apr 26 2017
ETFs with exposure to Lexicon Pharmaceuticals, Inc. : April 25, 2017 Apr 25 2017
Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US :... Apr 25 2017
3 Top Biotech Stocks to Buy in April Apr 03 2017
Lexicon To Present At The 16th Annual Needham Healthcare Conference Apr 03 2017
What Does Big Pharma Want To Buy? 3 Drugmakers On Merger Track Mar 31 2017
3 Tremendously Promising Diabetes Drugs Potentially on the Way Mar 26 2017
Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : LXRX-US :... Mar 20 2017
Surging Earnings Estimates Signal Good News for Lexicon (LXRX) Mar 15 2017
Lexicon To Present At The Barclays Global Healthcare Conference Mar 09 2017
Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
Lexicon To Present At The Cowen And Company 37th Annual Healthcare Conference Mar 06 2017
Edited Transcript of LXRX earnings conference call or presentation 3-Mar-17 3:00pm GMT Mar 03 2017
Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential Mar 03 2017
Biotech Premarket Movers: Karyopharm, Lexicon, Prothena Mar 03 2017
Lexicon reports 4Q loss Mar 03 2017
Biotech's Outlook Strengthens After President Trump's Speech: Today's Reports on Dynavax... Mar 02 2017
Lexicon To Report Fourth Quarter And Year End 2016 Financial Results On March 3, 2017 Mar 01 2017
Here’s What’s Next For Lexicon Pharmaceuticals, Inc. (LXRX) And Dynavax Technologies Corporation... Mar 01 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)